Prognostic value of plasma ST2 in patients with non-ST segment elevation acute coronary syndrome

Çağrı Kokkoz, Adnan Bilge, Mehmet Irik, Halil I Dayangaç, Mustafa Hayran, Funda Karbek Akarca, Nimet Bilal Erdem, Musa Çavuş, Çağrı Kokkoz, Adnan Bilge, Mehmet Irik, Halil I Dayangaç, Mustafa Hayran, Funda Karbek Akarca, Nimet Bilal Erdem, Musa Çavuş

Abstract

Objective: The aim of this study is to detect plasma ST2 levels in patients who were admitted to emergency department with chest pain and diagnosed with non st segment elevation myocardial infarction (NSTEMI) and to research the relationship between 28-day mortality and ST2 levels.

Methods: The present study was conducted at Emergency Department of Celal Bayar University Hafsa Sultan Hospital between September 2015 and January 2016 as a prospective, single-center, cross-sectional study. Plasma ST2 levels were detected in patients who were diagnosed with NSTEMI based on physical examination, ECG and troponin. The eligible patients were followed up with regard to mortality during 28 days.

Results: A total of 88 patients diagnosed with NSTEMI were included in the study and followed up for 28 days. While 18 (20.5%) patients died at the end of 28 days, 70 (79.5%) patients survived. Mean ST2 level of surviving 70 patients was 651.37 ± 985.66 pg/mL and mean ST2 level of dying 18 patients was 2253.66 ± 1721.15 pg/mL (p < 0.001). ST2 value was higher among the dying (non-survivors) compared to the survivors at the end of 28 days and this was found related to mortality. ST2 cut-off value was found as 1000 pg/mL with 72.2% sensitivity and 20.0% specificity.

Conclusion: Among the patients who were diagnosed with NSTEMI at the emergency department, ST2 levels on admission were found significantly higher among the non-survivors compared to the survivors. ST2 level was accepted as a reliable biomarker for prediction of 28 mortality in patients diagnosed with NSTEMI.

Figures

Fig. 1
Fig. 1
Graphical comparison of ST2 levels.
Fig. 2
Fig. 2
ROC curve analysis.
Fig. 3
Fig. 3
Kaplan-Meier survival curve according to ST2 level above and below optimal cutoff value for 28 days.

References

    1. Lloyd-Jones D., Adams R., Carnethon M. Heart disease and stroke statistics–2009 update: a report from the american heart association statistics committee and stroke statistics subcommittee. Circulation. 2009 Jan 27;119(3):e21–181.
    1. Savonitto S., Ardissino D., Granger C.B. Prognostic value of the admission electrocardiogram in acute coronary syndromes. J Am Med Assoc. 1999;281:707–713.
    1. Bassand J.P., Hamm C.W., Ardissino D. Guidelines for the diagnosis and treatment of non–ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;13:1598–1660.
    1. Morrow D.A., Cannon C.P., Jesse R.L. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem. 2007;53:552–574.
    1. Reiter M., Twerenbold R., Reichlin T. Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction. Heart. 2013;99:708–714.
    1. Daniels Lb, Clopton P., Iqbal N. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J. 2010 Oct;160(4):721–728.
    1. Pascual-Figal D.A., Ordoñez-Llanos J., Tornel P.L. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol. 2009 Dec 1;54(23):2174–2179.
    1. Aldous S.J., Richards A.M., Troughton R. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail. 2012 Apr;18(4):304–310.
    1. Shimpo M., Morrow D.A., Weinberg E.O. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186–2190.
    1. Socrates T., deFilippi C., Reichlin T. Interleukin family member ST2 and mortality in acute dyspnoea. J Intern Med. 2010 Nov;268(5):493–500.
    1. Bartunek J., Delrue L., van Durme F. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008;52:2166–2174.
    1. Eggers K.M., Armstrong P.W., Califf R.M. ST2 and mortality in nonST-segment elevation acute coronary syndrome. Am Heart J. 2010;159:788–794.
    1. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011;32:2999–3054.
    1. Cortese Francesca, Gesualdo Michele. A novel cardiac bio-marker: ST2: a review Marco Matteo Ciccone. Molecules. 2013;18:15314–15328.
    1. Dieplinger B., Mueller T. Soluble ST2 in heart failure. Clin Chim Acta. 2015 Mar 30;443:57–70.
    1. Shah R.V., Januzzi J.L., Jr. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep. 2010;7:9–14.
    1. Sabatine M.S., Morrow D.A., Higgins L.J. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117:1936–1944.
    1. Hollander J.E., Blomkalns A.L., Brogan G.X. Standardized reporting guidelines for studies evaluation risk stratification of emergency department patients with potential acute coronary syndromes. Ann Emerg Med. 2004;44:589–598.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner